

<https://doi.org/10.48047/AFJBS.6.7.2024.1151-1164>



African Journal of Biological Sciences

Journal homepage: <http://www.afjbs.com>



Research Paper

Open Access

PHAGE THERAPY AS AN ALTERNATIVE TO ANTIBIOTICS

Jiwon Hwang and Joohee Kim*

Department of Nursing, Kyungdong University Medical Campus, Wonju-si, Gangwondo 24695, Korea
chiwon0909@kduniv.ac.kr and joohee4085@kduniv.ac.kr

Volume6, Issue7, June 2024

Received: 25 April 2024

Accepted: 03 June 2024

Published: 21 June 2024

doi:10.48047/AFJBS.6.7.2024.1151-1164

ABSTRACT

Antibiotics are currently administered as a bacterial treatment, however, the emergence of multi-drug resistant bacteria has resulted in a need for alternative treatments. Development of alternative therapies is of particular importance in the effort to control the growth of microorganisms. Bacteriophages (phages), which have an inherent capacity for destruction of bacteria, are regarded as useful tools due to their specificity and their use is considered ecologically safe.

Phage therapy is typically reliant on the use of naturally occurring phages capable of infecting and dissolving bacteria at the site of infection. Advances in biotechnology have led to an expanded range of potential phage therapies including biotechnology phages as well as newly developed strategies for using purified phage lysis proteins. Current studies on the use of phage and lytic proteins, particularly for treatment of multidrug-resistant bacterial infections, have suggested that phage therapy may be useful as a replacement or supplement for antibiotic therapy. Therefore, there are many considerations when designing therapies for prevention and treatment of bacterial infections. Knowledge regarding the interaction between phage, bacteria, and human host is limited. However, considering evidence indicating that there are no significant side effects when used as a phage therapy, acceptance of phage therapy as a stepwise treatment to minimize suffering from infectious disease can be expected.

Keywords: Phage therapy, Multidrug-resistant bacteria, antibiotic therapy, infectious disease

INTRODUCTION

The idea that treating a bacterial virus for the bacterial infection is gained traction in response to the recent emergence of multidrug-resistant pathogens, but it has been almost a century. Early observations of phage-induced bacterial lysis, their biological properties as well as their therapeutic value have been controversial. Frederick Twort was the first to describe a characteristic area related to phage infection in 1915, but the origin of this phenomenon was attributed to the bacterial virus and the use of the term "bacteriophage" (literally "bacteria eater")(4). It was also d'Hérelle who devised the idea of using phage as a cure, and in 1919 Hôpital des Enfants-Malades in Paris reported the first case of clinical use of phage. Phage was successfully used in the treatment of four pediatric cases of bacterial dysentery(5). Despite its initial experimentation, d'Hérelle has achieved several successful results. And his research was strongly contested in the scientific community(6). Nonetheless d'Hérelle uses dysentery, cholera, and treatment of infectious diseases in the 20th century, has a series of phage therapy center and a commercial phage production facilities in Europe and India, Global continued pioneering phage therapy(7). 1931, one kind of test of phage therapy for the treatment of cholera in the Punjab region of India has included 118 patients and 73 control subjects who received the group phage therapy. d'Hérelle showed 74 deaths in the control group and only 5 deaths in the experimental group, a mortality rate of 90%(5).

There have been many mistakes in these early attempts to treat phage, and most probably did not understand the biological properties of the phage. The basic purification and storage protocol resulted in low potency of active phage and contamination from bacterial antigens, and phages that were not infectious to the target bacteria were used for treatment(4). In addition, the transmission of the phage to the infected area was embarrassing because of the medical limitations of the time. For example, the role of the innate immune response in patients who have removed active phage and reduced the efficacy of phage therapy has recently been observed as a physiological mechanism (8). As a result, phage therapy has been widely disseminated by most western medicine since the introduction of pharmaceutical antibiotics in the 1940s. Exceptions are in the former Soviet Union and Eastern Europe where clinical phage therapy has been extensively used to treat antibiotic resistant infections caused by a variety of infectious bacteria such as *Staphylococcus*, *Pseudomonas*, *Klebsiella*, and *E. coli*(9,10)

Phage Biology Basics

Phage, a naturally occurring bacterial parasite, cannot replicate independently and is ultimately reliant on its bacterial host for survival. Phages, simple but diverse biological organisms, are composed of DNA or RNA enclosed within a protein capsid. Phages typically bind to specific receptors on the surface of the bacterial cell, inject their genetic material into host cells, followed by integration of this material into the bacterial genome (so-called "temperate" phages) and its propagation vertically into daughter cells, or hijacking a bacterial cloning machine for production of next generation phage progeny and lysed cells (so-called "lytic" phages). When the phage progeny reaches critical mass, where some viral particles may contain more than 1000 virus particles depending on the environmental factors, the lytic protein is activated to hydrolyze the peptidoglycan cell wall to induce the release of new phages for resumption of the solute cycle (1,2).




Figure 1: Biological circulation of phage. First, the virus binds to bacterial cells, followed by injection of genetic material. In the cycle of viral replication, viral genetic material is integrated into the genome of the host, followed by replication of bacterial cells. During the solute cycle, the viral genetic material is replicated followed by synthesis of viral proteins. A set of virions is then established, followed by the dissolution of bacteria and the release of new virions (3).

Main Applications of Phage Therapy

As mentioned previously, phage therapy has been utilized for centuries. However, guidelines for conduct of clinical trials and research articles published in Russian or other non-English speaking languages are used only in other eastern countries. Therefore, phage therapy is not currently used in Europe and North American countries. Researchers are currently conducting testing for clinical trials. An interesting European project launched by the European Commission in 2013 is currently underway. This project is based on the use of phage cocktails for treatment of burn injuries infected with *Pseudomonas aeruginosa* or *E.coli*.

The primary use of phage therapy is for treatment of diseases and infections as well as for eradication of pathogenic bacteria capable of forming biofilms. Another interesting approach is the use of phage as a preventive disinfectant, particularly in the medical field and with use of clinical instruments. In addition, current technology or a combination of other technologies and phage can be helpful in addressing these clinical applications. Despite the effects of a single type of bacteriophage on bacterial strains due to their high specificity, phage cocktails are considered an interesting strategy for lowering the resistance of bacteria and solving problems related to their range of action (12). They typically consist of other bacteria capable of attacking other bacterial species or species. In this way, the phage cocktail is able to postpone the emergence of resistance to phage cocktail, thereby playing a decisive role in biofilm formation and the effects of a long-lasting grip. In addition, these cocktails have been proven to offer other benefits including decontaminating food by removing *E. coli*, *Salmonella enterica* or *Listeria* (13).

Phage therapy plays an important function in other areas, including external medical upcoming food production and livestock rearing. Phage, which can eradicate bacterial infections in animals and prevent ingestion of contaminated food, can be useful in ensuring food safety. One interesting example of the use of phage is for management of a typical food-related infection caused by *Salmonella* (salmonellosis), *Listeria monocytogenes*, *Campylobacter* or *Escherichia coli* (*E. coli*) (86).

Benefits and Drawbacks of Phage Therapy

Bacteriophage therapy, which can be administered as a treatment for bacterial diseases, offers several benefits, including its potential as a powerful tool in the effort to prevent the emergence of bacterial

resistance. One of the main concerns regarding antibiotics is that they can affect microorganisms associated with disease or human imbalance. Because of this connection, the specificity of the phage is based on the fact that replication will occur within a particular host (phage because they cannot infect eukaryotic cells) to resolve the problem. Unlike antibiotics, removal of phages can occur during rapid multiplication in the host, and (if you identify a host only), can be administered in small amounts, with long intervals between, and one population has been removed (14). Because phage replication can only occur in bacteria, the action of phage inside the host is unusual. Conversely, antibiotics are less accurate and cover more areas if the organism is free of bacteria (15).

Another benefit of phage is that it can be used on areas of the body that are difficult to reach, such as treatment of infections of the central nervous system, which can be a cause of serious problems (16). An important feature of phage is that it is capable of evolving, and antibiotics are considered static substances that do not change even when the environment changes. Another interesting feature of phage is isolation and production cost. The cost of producing antibiotics is economically high. Antibiotics are not naturally occurring and should be synthesized in the laboratory (17).

The substantial advantage of the specificity of the phage and the limitations of phage therapy is worth noting. Phage should be applied first to minimize potential damage to the microorganism, however, determining which bacteria is causing the disease in vitro is required. This can be a difficult process because rapid identification is required so that the patient can receive treatment (18,19). One method of overcoming this obstacle is to use a phage cocktail (14). However, in vitro and in vivo phage behavior may differ, and in vivo studies are insufficient to ensure an adequate effect (20).

The pharmacology of Phage can be very complex in pharmacokinetics (the action of phages inside the body) and pharmacodynamics (the function of the body on the phages) (21). In phage therapy, the interaction between phage and bacteria is related to pharmacokinetics. Regarding pharmacokinetics, this is believed to be related to the density of phage in the host. Smaller bacterial populations should require the use of large quantities of phage for more rapid replication when compared with bacteria. In addition, in the case of low bacterial density, replication of the phage will not occur rapidly enough and the desired action may not be carried out (22). This is an indication that there may be variation depending on the dose of phage. The dose of phage is dependent on bacterial density, phage particle size, and phage toxicity. The more toxic the phage is, the more likely it is to attack the host. The solution at this point is based on a toxic phage with a large burst size (producer of large offspring within a short time) and is administered specifically at the site of infection. In addition, there is potential for recognition of the phage or a product by the immune system for induction of an immune response. However, phage dissolution generally occurs more rapidly when compared with retention of neutralizing antibody. However, some researchers have suggested that the potential for an immune response may be related to release of the product and enzymes from the bacterial lysis. According to a recent study, the phage T4 is highly immunogenic and can be used as potential vaccine candidates (23). Also, in many cases, the immune response can be evaded by modifying the phage administration mode (21). Knowledge regarding the immune mechanism involved in detection along with continuous action on the phage is limited. Therefore, an evaluation of the effect of the phage on the human body by examining these substances is needed. By contrast, another study reported that the application of phage therapy had no direct effect on the patient (24). Despite the fact that the safety of a phage must be verified, phage is consumed indirectly whenever there is fermentation of food, breathing, or accidental drinking of seawater. Thus, bacteriophages do not appear to increase the potential risk (25). In addition to the pathways by which a phage can naturally reach a bacterial host, there is a new strategy for enhancing the longevity of bacteriophages. Liposomes or capsules around the alginate phage will be accompanied by different ions and must therefore be biocompatible. One question to be addressed is the physical limitations of this structure, and the most appropriate method for encapsulating a phage should be determined according to potential future capabilities (26). Above all, the most urgent issue to address is the lack of basic information related to dosage, dosage form, protocol, and the appropriate application of this therapy in certain cases of each type of phage (14,18). The main question is in regard to the difficulty of digging for a phage (because it is a natural entity) and the failure of pharmaceutical companies to accept this treatment (11). Legal regulations should be established to define the limitations and safe use of phage therapy. Finally, ethical and social acceptance of phage therapies is a major obstacle to the difficulty of believing that viruses are not only dangerous to humans, but also have the potential to cure diseases (3).

Phage against Clinically Significant Pathogens

Recent studies have examined the potential for application of phage therapy for management of clinically important pathogens using animal models. In the treatment of sepsis caused by *P. aeruginosa*, oral administration of phage resulted in a mortality rate of 0% in the experimental group and 66.7% in control mice (27). A single phage at the same time as administration of *C. difficile* in a hamster model of ileocectitis by *Clostridium difficile* (*C. difficile*) indicated sufficient precautions for infection. After treatment with phage, animals treated with *C. difficile* and clindamycin and control animals died within 9 hours and 11 out of 12 animals in the experimental group survived (28). The phage combination also caused significantly reduced in vitro growth of *C. difficile*, with limited growth in vivo using the hemostar model (40). Intraperitoneal administration of a single phage was sufficient to result in 100% rescue mice in a bacteremic model using vancomycin resistant *E. faecium* (30), *E. coli* (31) producing an expanded β -lactamase, and imipenem resistant *P. aeruginosa* (32). Promising results have also been obtained using phage cocktails for treatment similar to that for the skin, lungs, and antibiotic-resistant infection of the gastrointestinal tract with *P. aeruginosa* in animal models (27,33). Animal experiments using multidrug-resistant *E. coli* O25: H4-ST131(34), *Vibrio parahaemolyticus* (35), *S. aureus* (36), and *A. baumannii* have also been reported. As in the case of multidrug-resistant *P. aeruginosa*, evidence indicating that antibiotic-resistant bacteria can restore antibiotic susceptibility have also been reported (37).

Human experiments in the field of phage therapy have been conducted for nearly a century in various institutions in Eastern Europe, most notably the Eliava Institute for Immunology and Experimental Therapy in Wroclaw, Poland. *E. coli*, *S. aureus*, *Streptococcus spp.*, *P. aeruginosa*, *Proteus spp.*, *Salmonella spp.*, *S. dysenteriae* and *Enterococcus spp.*, have been used extensively in preclinical and clinical treatments of bacterial pathogens (38). Effective applications range from surgical treatment to gastrointestinal treatment and prophylactic treatment. In a series of six patients with antibiotic-resistant diabetic ulcers of the foot, topical application of *S. aureus*-specific phage resulted in recovery for all individuals (39). In a clinical trial conducted in 1938, bacterial dysentery (219 children, 138 children, 81 adults) was used only with phage cocktails composed of various phages, targeting *Shigella flexneri*, *Shigella shiga*, *E. coli*, *Proteus spp.*, and treatment with *P. aeruginosa* I was administered. *Salmonella typhi*, *Salmonella paratyphi A* and *B*, *Staphylococcus spp.*, *Streptococcus spp.*, and *Enterococcus spp.*; cocktails were administered in both oral and rectal form (40). Of the patients with a history of typhoid fever during the 1974 typhoid epidemic, 28% of the patients who complained of this symptom showed a 27% improvement within 2-3 days (40). A total of 18,577 children were participants in an interventional trial, which resulted in a 5-fold reduction in the incidence of typhoid fever compared with placebo, with the administration of phage indicating a more effective status for target pathogens when combined with antibiotics (41). The potential for phage treatment remains.

There are currently several commercial phage arrangements used for biocontrol of bacterial pathogens that do not have approved phage treatment products for human use in the European Union or the United States but are approved by the food industry as "typically considered safe" by the FDA. In 2011, approximately 48 million cases of food poisoning were reported in the United States alone. Available evidence has suggested that phage biocontrol can be an effective method for enhancing food safety at various stages of meat production and processing and also reduce bacterial contamination in fruits, vegetables, and dairy products. Recent placebo controlled human experiments, which demonstrated the safety of phage biocontrol and oral phage management in these types of food products, are gradually beginning to fill in the knowledge gap regarding the safety of phage therapy. These preparations are used mainly for *salmonella spp*, *Listeria monocytase*, MRSA, *E. coli* O157:H7, *Mycobacterium tuberculosis*, *Campylobacter spp*, and *Pseudomonas syringae* (42-45). There is also potential for detection of pathogens, an example of which is detection of bacillus anthracis using the violin reporter phage (45). There is increasing evidence of continued enhancement of phage safety with further randomization, double blind and placebo controlled phase I/II clinical trials of phage therapy, including the establishment of safety and efficacy simultaneously in treating chronic beards caused by antibiotic-resistant *P. aeruginosa* (46).

The innovation of gene editing tools CRISPR / Cas has led to creation of new opportunities for development of phage therapies. One example includes the use of a CRISPR / Cas for destruction of the antibiotic resistance gene for destruction of the antibiotic resistance plasmid using a biotechnology phage (47). This phage can be applied to surfaces in a hospital to reduce the frequency and spread of antibiotic resistance

genes. Although still in its infancy, the field of biotechnology using the phage will undoubtedly lead to development of many useful technologies (Table1)

Table 1.

Causative agent	Model	Condition	Result summary1
Vancomycin-resistant <i>Enterococcus faecium</i>	Murine	Bacteremia	100% reduced mortality
β -lactamase producing <i>E. coli</i>	Murine	Bacteremia	100% reduced mortality
Imipenem-resistant <i>P. aeruginosa</i>	Murine	Bacteremia	100% reduced mortality
<i>Acinetobacter baumannii</i> , <i>P. aeruginosa</i> and <i>S.aureus</i>	Murine	Sepsis	Animals protected against fatal dose of <i>A. baumannii</i> and <i>P. aeruginosa</i> but not <i>S. aureus</i>
<i>Escherichia coli</i>	Murine	Meningitis and Sepsis	100% and 50% reduced mortality for meningitis and sepsis, respectively
MDR <i>Vibrio parahaemolyticus</i>	Murine	Sepsis	92% and 84% reduced mortality for i.p. and oral routes, respectively
<i>S. aureus</i>	Rabbit	Wound infection	Co-administration with <i>S. aureus</i> prevented infection
MDR <i>S. aureus</i>	Human	Diabetic foot ulcer	All 6 treated patients recovered
Unclassified bacterial dysentery	Human	Dysentery	Phage cocktail improved symptoms of 74% of 219 patients
<i>Salmonella typhi</i>	Human	Typhoid	In cohort of 18577 children, phage treatment associated with 5-fold decrease in typhoid incidence compared to placebo
Antibiotic-resistant <i>P. aeruginosa</i>	Human	Chronic Otitis	Phage treatment safe and symptoms improved in double-blind, placebo-controlled Phase I/II trial
<i>Shigella dysenteriae</i>	Human	Dysentery	All four treated individuals recovered after 24 h
<i>Vibrio cholerae</i>	Human	Cholera	68 of 73 survived in treatment group and only 44 of 118 in control group
<i>Pseudomonas aeruginosa</i>	Murine	Sepsis	66.7% reduced mortality
<i>Clostridium difficile</i>	Hamster	Ileocectitis	Co-administration with <i>C. difficile</i> prevented infection
	Hamster	Ileocectitis	92% reduced mortality

Table 1. Published findings on phage therapy in humans and in animal models(4)

Application of Phage-Derived Lytic Proteins

While the bacterial host is melting, most phage species utilize two major classes of proteins. One is Transmembrane protein Holin and the other is endolysin (lysin), a peptide known as cell wall hydrolase. These two proteins work together to cause the destruction of bacterial cells (48). Although phage lysine can hydrolyze the bacterial cell wall alone, it cannot dissolve it. Therefore, lysine has received attention as a potential antibacterial agent. This protein can exert a powerful and rapid action and is inert to eukaryotic cells.

Lysins have been obtained successfully from mice in bacteremic strains including multidrug resistant *A. baumannii* (96), *Streptococcus pneumoniae* (50), and MRSA (51). Combined use of phage lysine and antibiotics may be more effective in eradicating the infection than in vitro and in vitro proven antibiotics alone in colon models using *C. difficile* (52). Phage lysin can cause destruction of plant cells, including *B. anthracis* lysin PlyG, which can attack spores in bacillus, a distinct advantage over antibiotics (53). Lysin can also be mass produced using common recombinant techniques. Genes for cysteine, histidine - dependent amiodo hydrolase/peptidase (CHAPK), derived from bacteriophage, were cloned and inserted into coliforms

for purification. CHAPK Lysin is effective for management of MRSA and it can cause dispersal of *S. aureus* biofilms (54).

Adding to the appeal of lysins as antibacterial agents, it is considered unlikely that bacteria will develop resistance to lysins due to the fact that they target sites on the peptidoglycan cell wall that are critical for bacterial viability (48). Operation recombinant phage lysis proteins are much easier to grip due to the short life span, mass production, and administration compared with the actual production of phage, which may be limited by the potential for removal and neutralization of antibodies produced by the host cells of the reticuloendothelial (8). Future potential for application of phage lysine includes the combination of lysine with the antibiotics considered more effective than antibiotics alone or lysine for treatment of pathogens such as MRSA and *C. difficile* in mice (55-57).

Table 2.

	Lytic enzyme	Model	Target pathogens
Phage-derived lysins	ABgp46	In vitro	MDR <i>Acinetobacter baumannii</i> , <i>Pseudomonas aeruginosa</i> , and <i>Salmonella typhimurium</i>
	PlyF307	Murine	MDR <i>A. baumannii</i>
	Cpl-1	Murine	<i>Streptococcus pneumoniae</i>
	Cocktail of 6 distinct lysins	In vitro and murine in vivo	MRSA
	PlyCD	In vitro and ex vivo	<i>Clostridium difficile</i>
	PlySs2	Murine	<i>Streptococcus pyogenes</i> and MRSA
	PlyG	In vitro	<i>Bacillus anthracis</i>
Lysin and antibiotic combination therapy	CF-301	Murine	MRSA
	MR-10	Murine	Burn wound infection
Bioengineered chimeric lysins	CHAPK	In vitro	MRSA
	ClyH	Murine	MRSA
	Cpl-711	Murine	<i>S. pneumoniae</i>
	Ply187	Murine	<i>Staphylococcus aureus</i>
	Artilyns	Nematode gut	<i>P. aeruginosa</i>
		Human keratinocytes	<i>A. baumannii</i>

Table 2: Recently published findings on phage lytic enzymes(4)

Phage Therapy vs Antibiotic Therapy

Antibiotics and phages both act as antimicrobial agents capable of breaking down bacterial colonies through dissolution or inhibition, however, there are some differences between antimicrobial agents depending on the situation.

Safety

The side effects of antibiotics have been well documented and include numerous gastrointestinal and blood academic complications, including anaphylaxis, renal toxicity, cardiac toxicity, liver toxicity, and neurotoxicity. Most are considered side effects. In such rare cases anaphylaxis is considered a product of a high tissue concentration, related to certain types of antibiotics (58-60). Contrary to the comprehensive human literature on antibiotic safety, phage therapy has recently gained attention in Western medicine, and there is currently a significant amount of information on phage safety. Although oral phage is generally considered safe (61-64), a major consideration for phage therapy is translocation of the phage across the intestinal epithelium, which is then circulated in the blood (65). Some data have indicated that translocation of phage through interleukin-2, inhibition of tumor necrosis factor, and generation of interferon gamma can be beneficial to the host by causing down-regulation of the immune response to the microbial antigen related to the intestinal-response (65). Other studies have reported that host innate immune responses resulted in elimination of phage following administration in rats (8). While phage therapists outweigh the shortcomings of nonimmune deficient patients, the immune response to phage can be suggestive of a

potential side effect in patients with immunodeficiency, which could lead to hypothetical worsening of the patient's condition. Thus far, other researchers have failed to agree on this possibility, maintaining that phage therapy is unlikely to cause such side effects in immunodeficient patients (38). Additional complications include the potential for failure of the intestinal barrier resulting from treatment with a phage cocktail. A mouse model was used to demonstrate that oral administration of a commercial Russian-made phage cocktail could increase the levels of plasma in inflammatory circulating immune complexes in the blood and increase intestinal permeability (67). It could be related to a variety of pathologies. However, another study did not report a significant increase in the level of cytokine in response to phage treatment (68). The potential of phage therapy, which can interfere with normal barrier function, can seriously affect recent disorders related to disorders of the intestinal barrier, such as Crohn's disease, inflammatory bowel disease (67). Pincus et al. reported that the inflammatory response to the phage was dependent on the affected area (69). Obviously, many safety problems related to the treatment of phage still need to be resolved. Physiological responses to the phage can vary based on the individual and may vary depending on the specific phage variants used (4). Because much of the current research on immunological response to phage is confined to animal models, conduct of future research should focus on clinical testing that includes humans to determine the safety of phage treatment in relation to human health.

Specificity Phage

Tends to be specific to species and strains, in contrast to antibiotics. In some cases, it can offer a substantial advantage considering that a wide range of antibiotics have been well documented and incidental to the symbiotic intestinal microflora that are known for causing secondary consequences such as antibiotic-associated diarrhea and *C. difficile* infection. Other consequences of antibiotic perturbation in the microbial community of the digestive tract include the risk of asthma, obesity, and diabetes (70-72). Although current understanding of the side effects of phage therapy is limited, compared to antibiotics, phage therapy is less prone to gastrointestinal microbial disruption, while effectively reducing intestinal transport of pathogens including *Shigella sonnei* and uropathogenic *Escherichia coli* (73-74).

Biofilm penetration

Despite the proven effectiveness of antibiotics against plankton bacteria including *Vibrio cholera* and the *Yersinia* plague, so far there have been limits to the treatment of bio-membrane-based bacterial infections (75). However, an enzyme (e.g. EPS) located outside the capsid of the phage causes the breakdown of extracellular polymeric substances (EPS) and dispersion of bacterial biological membranes to allow the phage to approach bacteria within the EPS matrix (60). Upon completion of the solute cycle, the exuded offspring of the phage will propagate the dispersion of the biofilm responsible for removal of bacteria from the biological membrane from the subsequent layer (60). Monitoring is required to determine whether or not antibiotics can inhibit the growth of bacteria when injecting a large amount of high-density biofilm, however, complete eradication by antibiotics is rare, and re-growth will begin to occur after treatment (76-77). Although many low-concentration antibiotics are generally regarded as non-toxic, high concentrations can be a cause of tissue toxicity (60). Gabisoniya et al. (78) of the Eliava Institute of Bacteriophages in Tbilisi, Georgia reported that the application of phage to in vitro colonies of the pathogen *P. aeruginosa* not only prevented additional formation of biofilm by pathogens, but also destroyed existing biofilms. Phage treatment prevented formation of biofilms by *L. monocytogenes*, *P. aeruginosa*, and *Staphylococcus epidermidis* from the surface of medical devices (79). These results are highly relevant to problems related to infection that persist due to the presence of implantable medical devices, such as catheters, lenses, and prostheses, where biofilm formation is common (4)

Phage cocktails

Due to the tremendous diversity of environmental phages, designing phage cocktails is more complex than the design of combination therapies that include antibiotics. The composition of the phage cocktail is important to ensuring the success of phage therapy. One of the pathological challenges when designing a phage cocktail is whether treatment should include the administration of a standardized cocktail or a customized cocktail. Cocktail design should also consider the phage life cycle. Lysozyme phage appears to be common in indigenous intestinal microorganisms, and prophage accounts for most of the gut virome (87). Some therapeutically promising solute phages can effectively silence virulence genes in pathogenic bacteria or provide genes for metabolism of short-chain fatty acids, while other lysogenic phages complement genes for toxicity and antibiotic resistance (80,81). This phage cocktail with an intelligent design consisted of four

phages not capable of dissolving the *A. baumannii* host and one phage capable of inhibiting growth only in vitro. Growth inhibition phages were selected for capsular loss against encapsulated *A. baumannii*. Eliminating the known toxic factor, the capsule can reduce bacterial virulence and is prone to dissolution in four additional phages (82). This type of cocktail design represents the start of a new treatment option for eradicating bacterial infections that show resistance to conventional therapies. Lysogenic phages have many interesting properties that may be useful in the on-site manipulation of an intracellular microbiome metagenome in an individual bacterium, potentially a human, however, knowledge of the role of lysogenic phage in the human intestine is needed first (83).

CONCLUSION

A major concern regarding antibiotics is that they can affect microorganisms associated with disease or human imbalance. Due to this connection, the phage is specific in that replication will occur within a particular host (phage because they cannot infect eukaryotic cells) thereby resolving the problem. Unlike antibiotics, removal of phages can occur when multiplication the host is a rapid occurrence, and (if a host only is found) can be administered in small amounts, with long intervals in between, and one population has been removed (14). Because phage replication occurs only in bacteria, action of the phage inside the host is unusual. Another benefit of phage is that it can be used on areas of the body that are difficult to reach, such as treatment of infections of the central nervous system, which can lead to serious problems (16). Although the safety of a phage must be verified, phage is consumed indirectly whenever there is fermenting food, breathing, or accidental drinking of seawater. That is the reason why bacteriophages do not appear to increase the potential risk (25).

Phage lysins have been obtained successfully from mice in bacteremic strains including multidrug resistant *A.baumannii* (49), *Streptococcus pneumoniae* (50), and MRSA (51). Combined administration of phage lysine and antibiotics may be more effective in eradicating the infection than in vitro and in vitro proven antibiotics alone in colon models using *C. difficile* (52). Future potential for application of phage lysine includes the combination of lysine with antibiotics considered more effective than antibiotics alone or lysine for treatment of pathogens such as MRSA and *C. difficile* in mice (55-57).

Liposomes, or capsules around the alginate phage, will be accompanied by different ions and must therefore be biocompatible. One question to be addressed is the physical limitations of this structure, and the most appropriate method of encapsulating phage should be determined according to potential capabilities (26)

The appropriate phage cocktail consisted of four phages not capable of dissolving the *A. baumannii* host and one phage capable of inhibiting growth only in vitro.

Growth inhibition phages were selected according to capsular loss against encapsulated *A. baumannii*. Eliminating the known toxic factor, the capsule can reduce bacterial virulence and is prone to dissolution in four additional phages (82). This type of cocktail design represents the establishment of a novel treatment option.

FUNDING: This research was supported by the Kyungdong University Research Fund.

REFERENCES

1. Delbrück M. The growth of bacteriophage and lysis of the host. *J Gen Physiol.* 1940;23:643–660.
2. Weinbauer MG. Ecology of prokaryotic viruses. *FEMS Microbiol Rev.* 2004;28:127–181.
3. Domingo-Calap P, Delgado-Martínez J. Bacteriophages: Protagonists of a Post-Antibiotic Era. *Antibiotics (Basel).* 2018;7(3):66. Published 2018 Jul 27. doi:10.3390/antibiotics7030066
4. Derek M Lin, Britt Koskella, Henry C Lin. Phage therapy: An alternative to antibiotics in the age of multi-drug resistance. *World J Gastrointest Pharmacol Ther.* 2017 Aug 6; 8(3): 162–173
5. Chanishvili N. Phage therapy--history from Twort and d'Herelle through Soviet experience to current approaches. *Adv Virus Res.* 2012;83:3–40.
6. Wittebole X, De Roock S, Opal SM. A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens. *Virulence.* 2014;5:226–235

7. Sulakvelidze A, Alavidze Z, Morris JG. Bacteriophage therapy. *Antimicrob Agents Chemother.* 2001;45:649–659.
8. Hodyra-Stefaniak K, Miernikiewicz P, Drapała J, Drab M, Jończyk-Matysiak E, Lecion D, Kaźmierczak Z, Beta W, Majewska J, Harhala M, et al. Mammalian Host-Versus-Phage immune response determines phage fate in vivo. *Sci Rep.* 2015;5:14802
9. Carlton RM. Phage therapy: past history and future prospects. *Arch Immunol Ther Exp (Warsz)* 1999;47:267–274.
10. Weber-Dabrowska B, Mulczyk M, Górski A. Bacteriophage therapy of bacterial infections: an update of our institute's experience. *Arch Immunol Ther Exp (Warsz)* 2000;48:547–551.
11. Reardon S. Phage therapy gets revitalized. *Nature.* 2014;510:15–16. doi: 10.1038/510015a.
12. Pires D., Melo L., Vilas Boas D., Sillankorva S., Azeredo J. Phage therapy as an alternative or complementary strategy to prevent and control biofilm-related infections. *Curr. Opin. Microbiol.* 2017;39:48–56.
13. Knoll B., Mylonakis E. Antibacterial bioagents based on principles of bacteriophage biology: An overview. *Clin. Infect. Dis.* 2013;58:528–534. doi: 10.1093/cid/cit771.
14. El-Shibiny A., El-Sahhar S. Bacteriophages: The possible solution to treat infections caused by pathogenic bacteria. *Can. J. Microbiol.* 2017;63:865–879. doi: 10.1139/cjm-2017-0030.
15. Golkar Z., Bagasra O., Pace D. Bacteriophage therapy: A potential solution for the antibiotic resistance crisis. *J. Infect. Dev. Ctries.* 2014;8:129–136. doi: 10.3855/jidc.3573.
16. Wittebole X., De Roock S., Opal S. A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens. *Virulence.* 2013;5:226–235. doi: 10.4161/viru.25991.
17. Matsuzaki S., Uchiyama J., Takemura-Uchiyama I., Daibata M. Perspective: The age of the phage. *Nature.* 2014;509 doi: 10.1038/509S9a.
18. Torres-Barceló C., Hochberg M. Evolutionary rationale for phages as complements of antibiotics. *Trends Microbiol.* 2016;24:249–256. doi: 10.1016/j.tim.2015.12.011.
19. Kutateladze M., Adamia R. Bacteriophages as potential new therapeutics to replace or supplement antibiotics. *Trends Biotechnol.* 2010;28:591–595. doi: 10.1016/j.tibtech.2010.08.001.
20. Ghannad M., Mohammadi A. Bacteriophage: Time to re-evaluate the potential of phage therapy as a promising agent to control multidrug-resistant bacteria. *Iran. J. Basic Med. Sci.* 2012;15:693–701.
21. Forde A., Hill C. Phages of life-the path to pharma. *Br. J. Pharmacol.* 2018;175:412–418. doi: 10.1111/bph.14106.
22. Levin B., Bull J. Opinion: Population and evolutionary dynamics of phage therapy. *Nat. Rev. Microbiol.* 2004;2:166–173. doi: 10.1038/nrmicro822
23. Tao P., Zhu J., Mahalingam M., Batra H., Rao V.B. Bacteriophage T4 nanoparticles for vaccine delivery against infectious diseases. *Adv. Drug Deliv. Rev.* 2018;6 doi: 10.1016/j.addr.2018.06.025.
24. Roach D., Debarbieux L. Phage therapy: Awakening a sleeping giant. *Emerg. Top. Life Sci.* 2017;1:93–103. doi: 10.1042/ETLS20170002.
25. Sarker S., McCallin S., Barretto C., Berger B., Pittet A.C., Sultana S., Krause L., Huq S., Bibiloni R., Bruttin A., et al. Oral T4-like phage cocktail application to healthy adult volunteers from Bangladesh. *Virology.* 2012;434:222–232. doi: 10.1016/j.virol.2012.09.002.
26. Cortés P., Cano-Sarabia M., Colom J., Otero J., MasPOCH D., Llagostera M. Nano/Micro formulations for bacteriophage delivery. *Methods Mol. Biol.* 2018;1693:271–283.
27. Watanabe R, Matsumoto T, Sano G, Ishii Y, Tateda K, Sumiyama Y, Uchiyama J, Sakurai S, Matsuzaki S, Imai S, et al. Efficacy of bacteriophage therapy against gut-derived sepsis caused by *Pseudomonas aeruginosa* in mice. *Antimicrob Agents Chemother.* 2007;51:446–452.

28. Ramesh V, Fralick JA, Rolfe RD. Prevention of *Clostridium difficile*-induced ileocectitis with bacteriophage. *Anaerobe*. 1999;5:69–78.
29. Nale JY, Spencer J, Hargreaves KR, Buckley AM, Trzepiński P, Douce GR, Clokie MR. Bacteriophage Combinations Significantly Reduce *Clostridium difficile* Growth In Vitro and Proliferation In Vivo. *Antimicrob Agents Chemother*. 2016;60:968–981.
30. Biswas B, Adhya S, Washart P, Paul B, Trostel AN, Powell B, Carlton R, Merrill CR. Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant *Enterococcus faecium*. *Infect Immun*. 2002;70:204–210.
31. Wang J, Hu B, Xu M, Yan Q, Liu S, Zhu X, Sun Z, Tao D, Ding L, Reed E, et al. Therapeutic effectiveness of bacteriophages in the rescue of mice with extended spectrum beta-lactamase-producing *Escherichia coli* bacteremia. *Int J Mol Med*. 2006;17:347–355.
32. Wang J, Hu B, Xu M, Yan Q, Liu S, Zhu X, Sun Z, Reed E, Ding L, Gong J, et al. Use of bacteriophage in the treatment of experimental animal bacteremia from imipenem-resistant *Pseudomonas aeruginosa*. *Int J Mol Med*. 2006;17:309–317.
33. Soothill JS. Treatment of experimental infections of mice with bacteriophages. *J Med Microbiol*. 1992;37:258–261.
34. Pouillot F, Chomton M, Blois H, Courroux C, Noelig J, Bidet P, Bingen E, Bonacorsi S. Efficacy of bacteriophage therapy in experimental sepsis and meningitis caused by a clone O25b: H4-ST131 *Escherichia coli* strain producing CTX-M-15. *Antimicrob Agents Chemother*. 2012;56:3568–3575.
35. Jun JW, Shin TH, Kim JH, Shin SP, Han JE, Heo GJ, De Zoysa M, Shin GW, Chai JY, Park SC. Bacteriophage therapy of a *Vibrio parahaemolyticus* infection caused by a multiple-antibiotic-resistant O3: K6 pandemic clinical strain. *J Infect Dis*. 2014;210:72–78.
36. Wills QF, Kerrigan C, Soothill JS. Experimental bacteriophage protection against *Staphylococcus aureus* abscesses in a rabbit model. *Antimicrob Agents Chemother*. 2005;49:1220–1221.
37. Chan BK, Sstrom M, Wertz JE, Kortright KE, Narayan D, Turner PE. Phage selection restores antibiotic sensitivity in MDR *Pseudomonas aeruginosa*. *Sci Rep*. 2016;6:26717.
38. Kutateladze M, Adamia R. Phage therapy experience at the Eliava Institute. *Med Mal Infect*. 2008;38:426–430.
39. Fish R, Kutter E, Wheat G, Blasdel B, Kutateladze M, Kuhl S. Bacteriophage treatment of intransigent diabetic toe ulcers: a case series. *J Wound Care*. 2016;25 Suppl 7:S27–S33.
40. Chanishvili N, Sharp R. Bacteriophage therapy: experience from the Eliava Institute, Georgia. *Microbiol Australia*. 2008;29:96–101.
41. Kutateladze M, Adamia R. Bacteriophages as potential new therapeutics to replace or supplement antibiotics. *Trends Biotechnol*. 2010;28:591–595.
42. Monk AB, Rees CD, Barrow P, Hagens S, Harper DR. Bacteriophage applications: where are we now? *Lett Appl Microbiol*. 2010;51:363–369.
43. Nannapaneni R, Soni KA. USA: John Wiley & Sons, Ltd; 2015. Use of Bacteriophages to Remove Biofilms of *Listeria monocytogenes* and other Foodborne Bacterial Pathogens in the Food Environment. *Biofilms in the Food Environment*, Second Edition; pp. 131–144.
44. Endersen L, O'Mahony J, Hill C, Ross RP, McAuliffe O, Coffey A. Phage therapy in the food industry. *Annu Rev Food Sci Technol*. 2014;5:327–349.
45. Schofield DA, Sharp NJ, Vandamm J, Molineux IJ, Spreng KA, Rajanna C, Westwater C, Stewart GC. *Bacillus anthracis* diagnostic detection and rapid antibiotic susceptibility determination using 'bioluminescent' reporter phage. *J Microbiol Methods*. 2013;95:156–161.

46. Wright A, Hawkins CH, Anggård EE, Harper DR. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant *Pseudomonas aeruginosa*; a preliminary report of efficacy. *Clin Otolaryngol*. 2009;34:349–357.
47. Yosef I, Manor M, Kiro R, Qimron U. Temperate and lytic bacteriophages programmed to sensitize and kill antibiotic-resistant bacteria. *Proc Natl Acad Sci USA*. 2015;112:7267–7272.
48. Roach DR, Donovan DM. Antimicrobial bacteriophage-derived proteins and therapeutic applications. *Bacteriophage*. 2015;5:e1062590.
49. Lood R, Winer BY, Pelzek AJ, Diez-Martinez R, Thandar M, Euler CW, Schuch R, Fischetti VA. Novel phage lysin capable of killing the multidrug-resistant gram-negative bacterium *Acinetobacter baumannii* in a mouse bacteremia model. *Antimicrob Agents Chemother*. 2015;59:1983–1991.
50. Witzernath M, Schmeck B, Doehn JM, Tschernig T, Zahlten J, Loeffler JM, Zemlin M, Müller H, Gutbier B, Schütte H, et al. Systemic use of the endolysin Cpl-1 rescues mice with fatal pneumococcal pneumonia. *Crit Care Med*. 2009;37:642–649.
51. Schmelcher M, Shen Y, Nelson DC, Eugster MR, Eichenseher F, Hanke DC, Loessner MJ, Dong S, Pritchard DG, Lee JC, et al. Evolutionarily distinct bacteriophage endolysins featuring conserved peptidoglycan cleavage sites protect mice from MRSA infection. *J Antimicrob Chemother*. 2015;70:1453–1465.
52. Wang Q, Euler CW, Delaune A, Fischetti VA. Using a Novel Lysin To Help Control *Clostridium difficile* Infections. *Antimicrob Agents Chemother*. 2015;59:7447–7457.
53. Yang H, Wang DB, Dong Q, Zhang Z, Cui Z, Deng J, Yu J, Zhang XE, Wei H. Existence of separate domains in lysin PlyG for recognizing *Bacillus anthracis* spores and vegetative cells. *Antimicrob Agents Chemother*. 2012;56:5031–5039.
54. Keary R, Sanz-Gaitero M, van Raaij MJ, O'Mahony J, Fenton M, McAuliffe O, Hill C, Ross RP, Coffey A. Characterization of a Bacteriophage-Derived Murein Peptidase for Elimination of Antibiotic-Resistant *Staphylococcus aureus*. *Curr Protein Pept Sci*. 2016;17:183–190.
55. Schuch R, Lee HM, Schneider BC, Sauve KL, Law C, Khan BK, Rotolo JA, Horiuchi Y, Couto DE, Raz A, et al. Combination therapy with lysin CF-301 and antibiotic is superior to antibiotic alone for treating methicillin-resistant *Staphylococcus aureus*-induced murine bacteremia. *J Infect Dis*. 2014;209:1469–1478.
56. Chopra S, Harjai K, Chhibber S. Potential of combination therapy of endolysin MR-10 and minocycline in treating MRSA induced systemic and localized burn wound infections in mice. *Int J Med Microbiol*. 2016;306:707–716.
57. Wittekind M, Schuch R. Cell wall hydrolases and antibiotics: exploiting synergy to create efficacious new antimicrobial treatments. *Curr Opin Microbiol*. 2016;33:18–24.
58. Rouveix B. Antibiotic safety assessment. *Int J Antimicrob Agents*. 2003;21:215–221.
59. Shehab N, Patel PR, Srinivasan A, Budnitz DS. Emergency department visits for antibiotic-associated adverse events. *Clin Infect Dis*. 2008;47:735–743.
60. Abedon ST. Ecology of Anti-Biofilm Agents I: Antibiotics versus Bacteriophages. *Pharmaceuticals (Basel)* 2015;8:525–558.
61. Bruttin A, Brüssow H. Human volunteers receiving *Escherichia coli* phage T4 orally: a safety test of phage therapy. *Antimicrob Agents Chemother*. 2005;49:2874–2878.
62. Merabishvili M, Pirnay JP, Verbeken G, Chanishvili N, Tediashvili M, Lashkhi N, Glonti T, Krylov V, Mast J, Van Parys L, et al. Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. *PLoS One*. 2009;4:e4944.

63. McCallin S, Alam Sarker S, Barretto C, Sultana S, Berger B, Huq S, Krause L, Bibiloni R, Schmitt B, Reuteler G, et al. Safety analysis of a Russian phage cocktail: from metagenomic analysis to oral application in healthy human subjects. *Virology*. 2013;443:187–196.
64. Sarker SA, Sultana S, Reuteler G, Moine D, Descombes P, Charton F, Bourdin G, McCallin S, Ngom-Bru C, Neville T, et al. Oral Phage Therapy of Acute Bacterial Diarrhea With Two Coliphage Preparations: A Randomized Trial in Children From Bangladesh. *EBioMedicine*. 2016;4:124–137.
65. Górski A, Wazna E, Dabrowska BW, Dabrowska K, Switała-Jeleń K, Miedzybrodzki R. Bacteriophage translocation. *FEMS Immunol Med Microbiol*. 2006;46:313–319.
66. Park K, Cha KE, Myung H. Observation of inflammatory responses in mice orally fed with bacteriophage T7. *J Appl Microbiol*. 2014;117:627–633.
67. Tetz G, Tetz V. Bacteriophage infections of microbiota can lead to leaky gut in an experimental rodent model. *Gut Pathog*. 2016;8:33.
68. Hong Y, Thimmapuram J, Zhang J, Collings CK, Bhide K, Schmidt K, Ebner PD. The impact of orally administered phages on host immune response and surrounding microbial communities. *Bacteriophage*. 2016;6:e1211066.
69. Pincus NB, Reckhow JD, Saleem D, Jammeh ML, Datta SK, Myles IA. Strain Specific Phage Treatment for *Staphylococcus aureus* Infection Is Influenced by Host Immunity and Site of Infection. *PLoS One*. 2015;10:e0124280.
70. Metsälä J, Lundqvist A, Virta LJ, Kaila M, Gissler M, Virtanen SM. Prenatal and post-natal exposure to antibiotics and risk of asthma in childhood. *Clin Exp Allergy*. 2015;45:137–145.
71. Cox LM, Blaser MJ. Antibiotics in early life and obesity. *Nat Rev Endocrinol*. 2015;11:182–190.
72. Mikkelsen KH, Allin KH, Knop FK. Effect of antibiotics on gut microbiota, glucose metabolism and body weight regulation: a review of the literature. *Diabetes Obes Metab*. 2016;18:444–453.
73. Mai V, Ukhanova M, Reinhard MK, Li M, Sulakvelidze A. Bacteriophage administration significantly reduces *Shigella* colonization and shedding by *Shigella*-challenged mice without deleterious side effects and distortions in the gut microbiota. *Bacteriophage*. 2015;5(4):e1088124. Published 2015 Aug 28. doi:10.1080/21597081.2015.1088124.
74. Galtier M, De Sordi L, Maura D, Arachchi H, Volant S, Dillies MA, Debarbieux L. Bacteriophages to reduce gut carriage of antibiotic resistant uropathogens with low impact on microbiota composition. *Environ Microbiol*. 2016;18:2237–2245.
75. Costerton JW. Introduction to biofilm. *Int J Antimicrob Agents*. 1999;11:217–221; discussion 237-239.
76. Anwar H, Strap JL, Chen K, Costerton JW. Dynamic interactions of biofilms of mucoid *Pseudomonas aeruginosa* with tobramycin and piperacillin. *Antimicrob Agents Chemother*. 1992;36:1208–1214.
77. Amorena B, Gracia E, Monzón M, Leiva J, Oteiza C, Pérez M, Alabart JL, Hernández-Yago J. Antibiotic susceptibility assay for *Staphylococcus aureus* in biofilms developed in vitro. *J Antimicrob Chemother*. 1999;44:43–55.
78. Gabisoniya TG, Loladze MZ, Nadiradze MM, Chakhunashvili NK, Alibegashvili MG, Tamarashvili NG, Pushkina VA. Effects of bacteriophages on biofilm formation by strains of *Pseudomonas aeruginosa*. *Appl Biochem Microbiol*. 2016;52:293–297.
79. Motlagh AM, Bhattacharjee AS, Goel R. Biofilm control with natural and genetically-modified phages. *World J Microbiol Biotechnol*. 2016;32:67.
80. Penadés JR, Chen J, Quiles-Puchalt N, Carpena N, Novick RP. Bacteriophage-mediated spread of bacterial virulence genes. *Curr Opin Microbiol*. 2015;23:171–178.
81. Modi SR, Lee HH, Spina CS, Collins JJ. Antibiotic treatment expands the resistance reservoir and ecological network of the phage metagenome. *Nature*. 2013;499:219–222.

82. Regeimbal JM, Jacobs AC, Corey BW, Henry MS, Thompson MG, Pavlicek RL, Quinones J, Hannah RM, Ghebremedhin M, Crane NJ, et al. Personalized Therapeutic Cocktail of Wild Environmental Phages Rescues Mice from *Acinetobacter baumannii* Wound Infections. *Antimicrob Agents Chemother.* 2016;60:5806–5816.
83. Sheth RU, Cabral V, Chen SP, Wang HH. Manipulating Bacterial Communities by in situ Microbiome Engineering. *Trends Genet.* 2016;32:189–200.
84. Sanjay Chhibber, Tarsem Kaur, Sandeep Kaur Co-Therapy Using Lytic Bacteriophage and Linezolid: Effective Treatment in Eliminating Methicillin Resistant *Staphylococcus aureus* (MRSA) from Diabetic Foot Infections
PLoS One. 2013; 8(2): e56022. Published online 2013 Feb 13. doi: 10.1371/journal.pone.0056022
85. Taha OA, Connerton PL, Connerton IF, El-Shibiny A. Bacteriophage ZCKP1: A Potential Treatment for *Klebsiella pneumoniae* Isolated From Diabetic Foot Patients. *Front Microbiol.* 2018;9:2127. Published 2018 Sep 11. doi:10.3389/fmicb.2018.02127
86. Carvalho, Carla M., et al. *Phages as therapeutic tools to control major foodborne pathogens: Campylobacter and Salmonella.* Rijeka: InTech, 2012.
87. Bryan CS, Reynolds KL, Metzger WT. Bacteremia in diabetic patients: comparison of incidence and mortality with nondiabetic patients. *Diabetes Care.* 1985;8(3):244–9.